Revenue: As of FY2025, the actual value is USD 6.162 M.EPS: As of FY2025, the actual value is USD -8.66.EBIT: As of FY2025, the actual value is USD -10.55 M.<h4>Consolidated Revenue</h4>Consolidated revenue for bioAffinity Technologies, Inc. decreased by approximately 34% to $6.2 million in 2025, from $9.4 million in 2024, primarily due to strategic actions to discontinue unprofitable pathology services and reduce costs .<h4>CyPath® Lung Testing Revenue</h4>CyPath® Lung testing revenue increased by approximately 87% to $963,000 in 2025, compared to $516,000 in 2024 . The total number of CyPath® Lung test results delivered increased by 99%, exceeding 1,200 for 2025 .<h4>PPLS Revenue Breakdown</h4><ul><li>Patient service fees: $4,917,342 in 2025 vs. $8,175,670 in 2024 .</li><li>Histology service fees: $1,116,912 in 2025 vs. $1,103,751 in 2024 .</li><li>Medical director fees: $68,268 in 2025 vs. $66,576 in 2024 .</li><li>Department of Defense observational studies: $577 in 2025 vs. $8,654 in 2024 .</li><li>Other revenues: $4,860 in 2025 vs. $7,371 in 2024 .</li><li>Total net revenue: $6,161,959 in 2025 vs. $9,362,022 in 2024 .</li></ul><h4>Operating Expenses</h4>Total operating expenses decreased by 9% to $16.7 million in 2025, compared to $18.3 million in 2024 . Direct costs and expenses: Decreased by approximately $1.8 million, or 29%, to $4.2 million in 2025 from $6.0 million in 2024 . Research and development: Remained consistent at $1.4 million in 2025 vs. $1.5 million in 2024 . Clinical development: Increased by approximately $384,000, or 119%, to $706,000 in 2025 from $322,000 in 2024 . Selling, general and administrative: Remained level at approximately $9.9 million for both 2025 and 2024 . Depreciation and amortization: Decreased by approximately $101,000, or 17%, to $505,000 in 2025 from $606,000 in 2024 .<h4>Other Income (Expense)</h4>Total other income (expense), net was - $4.3 million in 2025 compared to approximately - $75,000 in 2024 . This included: Interest (expense) income, net: - $20,987 in 2025 vs. - $74,865 in 2024 . Other (expense) income, net: - $461,939 in 2025 vs. $129 in 2024 . Gain (loss) on remeasurement of warrant liabilities: - $3,810,278 in 2025 vs. $0 in 2024 .<h4>Net Loss</h4>Net loss was - $14.9 million in 2025, compared to - $9.0 million in 2024 .<h4>Cash Flow</h4><ul><li>Net cash used in operating activities: - $9.3 million in 2025 vs. - $7.3 million in 2024, an increase of approximately $2.0 million in cash used .</li><li>Net cash used in investing activities: - $61,000 in 2025 vs. - $79,000 in 2024 .</li><li>Net cash provided by financing activities: $14.7 million in 2025 vs. $5.6 million in 2024 .</li><li>Cash and cash equivalents at end of year: $6.4 million in 2025 vs. $1.1 million in 2024 .</li></ul><h4>Other Key Financial Metrics</h4><ul><li>Gross proceeds from equity transactions: Approximately $16.9 million raised in 2025 to fund operating activities .</li><li>Accumulated deficit: Approximately - $68.6 million as of December 31, 2025 .</li><li>Working capital surplus: $4.7 million as of December 31, 2025 .</li></ul><h4>Outlook / Guidance</h4>bioAffinity Technologies, Inc. expects continued significant operating losses but anticipates increased revenue from accelerating CyPath® Lung sales and cost-saving measures . The company plans to expand CyPath® Lung into broader U.S. markets in 2026, including a longitudinal clinical trial, and aims to secure strategic partners for EU and Asia market entry . Management expects current cash resources to be sufficient through June 2026, but additional capital will be required for future operations and product development .

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 10-K: FY2025 Revenue: USD 6.162 M